Cue Biopharma

Evolving into a clinical-stage organization

Creating new safe and efficacious immunotherapies for patients

Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. This approach leverages a natural immune response with innovative protein engineering to achieve a more controlled immune response providing greater patient benefit while reducing toxicity — areas that have traditionally challenged broadly-acting immunotherapies on the market. In a push to move new safe and efficacious immunotherapies to patients, Cue Biopharma has scaled and grown into a clinical-stage company by expanding its development work in-house.


Non-standardized data capture

Excel sheets were flexible but difficult to manage at scale. This led to tedious data reconciliation when attempting larger analysis.

Barriers to communication and handoffs between teams

Rapid scaling, combined with the difficulty inherent in bridging research and development, led to collaboration challenges.

Growing into early development

Cue Biopharma wanted to evolve into a clinical-stage organization and needed to put in place the digital infrastructure necessary to do so.


Generating R&D insights

Consistent, structured data capture in templates allowed deeper insights to be drawn across experiments.

Cross-team collaboration

Collaboration and handoffs between teams - particularly between research and development - are efficient and effortless.

Centralized project management

Cue Biopharma is clinical-stage ready and has a 360-degree view of scientific progress driving outcomes.

Powering breakthroughs for over 1,200 biotechnology companies, from startups to Fortune 500s

Helix Image